Register
Medicines reference
Product

Milbemax

Milbemycin oxime + Praziquantel · Elanco

4 forms: scored tablet, tablet. No registration in force in Georgia.

Forms and doses0 of 4 in force in Georgia

The dose from the product's label, by species and weight. Check the label of the pack you use.

Choose species and weight; the matching row will be highlighted.
Form Species Weight Dose Frequency Georgia
2.5 mg/25 mg, Scored tablet · Cat Any weight Cat Any weight No dose for this species
This tablet is for dogs; no feline dose is provided on the label. The feline milbemycin dose is fourfold higher at 2 mg/kg; use Milbemax 4/10 mg or 16/40 mg.
- Georgia No
2.5 mg/25 mg, Scored tablet · Dog 0.5–1 kg Dog 0.5–1 kg 1/2 tablet
Minimum recommended dose rate: 0.5 mg of milbemycin oxime and 5 mg of praziquantel per kg are given once. 0.5 – 1 kg ½ tablet > 1 - 5 kg 1 tablet > 5-10 kg 2 tablets Do not use in puppies of less than 2 weeks of age and/or weighing less than 0.5 kg. the recommended dose should be strictly observed The use in dogs suffering from microfilaremia is thus not recommended. Can be used during pregnancy and lactation.
· once
once Georgia No
2.5 mg/25 mg, Scored tablet · Dog 1–5 kg Dog 1–5 kg 1 tablet
> 1 - 5 kg 1 tablet
· once
once Georgia No
2.5 mg/25 mg, Scored tablet · Dog 5–10 kg Dog 5–10 kg 2 tablets
> 5-10 kg 2 tablets
· once
once Georgia No
Details: pack, label wording, sources, registration

Milbemax 2.5 mg/25 mg, Scored tablet

milbemycin oxime 2.5 mg + praziquantel 25 mg, tablet for dogs 0.5-10 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
8.6/10
Very good
vetman assessment

Milbemax

2.5 mg/25 mg, milbemycin oxime 2.5 mg + praziquantel 25 mg, tablet for dogs 0.5-10 kg
Assessed clinical scopeDog · Full labelled species-specific scope for mixed susceptible cestode and nematode infections, with applicable eyeworm, lungworm or heartworm roles only when the fixed combination is indicated · By mouth
Care settingWeight-band tablet given with or after food after parasite identification, heartworm-risk assessment and confirmation that both active components are clinically justified
vetman score 8.6/10 Very good
Evidence confidence: High Georgia: No · Verified on 15 Oct 2026

A mature, strongly supported broad anthelmintic combination for correctly selected mixed infections; absence from the reviewed Georgian register does not negate its evidence, but local legal supply and the exact label must be checked.

Regulatory and scientific credibility9.0/10

A mature reference line with current UK authorisations and extensive post-authorisation history; the exact forms are not registered in the reviewed Georgian register.

Clinical efficacy9.0/10

Controlled and field studies support broad cestode and nematode efficacy, including label-specific eyeworm and heartworm roles; the evidence base is mature but target and regimen remain parasite-specific.

Safety and tolerability8.0/10

Safety is generally favourable at labelled doses, but microfilaraemic animals can react, MDR1-sensitive dogs need strict dosing, severe renal or hepatic dysfunction and very young or underweight animals require label-specific restrictions, and neurologic or gastrointestinal adverse effects can occur.

Clinical practicality8.5/10

Weight-band tablets and single-dose intestinal-worm treatment are practical, but administration with food, accurate half-tablet use where authorised and parasite-specific weekly or monthly repeat schedules must be followed; unnecessary repeated praziquantel should be avoided.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Use the fixed combination only when cestodes and nematodes, heartworm prevention or another exact combined label role are indicated at the same time; avoid unnecessary exposure to either component.
  • Before heartworm prevention or treatment in an endemic area, establish infection and microfilariae status; a high circulating microfilarial burden can cause acute hypersensitivity-type reactions after treatment.
  • Use caution with other macrocyclic lactones or P-glycoprotein substrates/inhibitors and follow the exact label; toxicity risk can rise in susceptible patients.
  • For Dipylidium, control fleas and chewing lice to prevent reinfection; for Echinococcus, apply local zoonosis reporting, hygiene and disposal requirements.
  • Weigh accurately and observe minimum age and weight limits. In Collies, related breeds or suspected MDR1 deficiency, never exceed the label dose; severe renal or hepatic dysfunction requires the exact label benefit-risk restriction.
Assessment sources
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Formulation Type
Scored tablet
Administration route
By mouth
Manufacturer
Elanco · United States
Registration
Georgia No
EU Yes, veterinary
Verified on: 15 Oct 2026
UK Yes, veterinary
Verified on: 15 Oct 2026
US No
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
DoseSpeciesWeightRouteFrequencySource
No dose for this species
This tablet is for dogs; no feline dose is provided on the label. The feline milbemycin dose is fourfold higher at 2 mg/kg; use Milbemax 4/10 mg or 16/40 mg.
Cat Any weight By mouth - Product label (SPC)
1/2 tablet
Minimum recommended dose rate: 0.5 mg of milbemycin oxime and 5 mg of praziquantel per kg are given once. 0.5 – 1 kg ½ tablet > 1 - 5 kg 1 tablet > 5-10 kg 2 tablets Do not use in puppies of less than 2 weeks of age and/or weighing less than 0.5 kg. the recommended dose should be strictly observed The use in dogs suffering from microfilaremia is thus not recommended. Can be used during pregnancy and lactation.
Dog 0.5–1 kg By mouth once Product label (SPC)
1 tablet
> 1 - 5 kg 1 tablet
Dog 1–5 kg By mouth once Product label (SPC)
2 tablets
> 5-10 kg 2 tablets
Dog 5–10 kg By mouth once Product label (SPC)
4 mg/10 mg, Scored tablet · Cat 0.5–1 kg Cat 0.5–1 kg 1/2 tablet
Minimum recommended dose rate: 2 mg of milbemycin oxime and 5 mg of praziquantel per kg are given as a single dose. 0.5 – 1 kg ½ tablet > 1 - 2 kg 1 tablet Do not use in cats of less than 6 weeks of age and/or weighing less than 0.5 kg. Can be used during pregnancy and lactation.
· once
once Georgia No
4 mg/10 mg, Scored tablet · Cat 1–2 kg Cat 1–2 kg 1 tablet
> 1 - 2 kg 1 tablet
· once
once Georgia No
4 mg/10 mg, Scored tablet · Dog Any weight Dog Any weight No dose for this species
This tablet is for cats; no canine dose is provided on the label. For dogs, use Milbemax 2.5/25 mg or 12.5/125 mg.
- Georgia No
Details: pack, label wording, sources, registration

Milbemax 4 mg/10 mg, Scored tablet

milbemycin oxime 4 mg + praziquantel 10 mg, film-coated tablet for cats 0.5-2 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Cat
8.6/10
Very good
vetman assessment

Milbemax

4 mg/10 mg, milbemycin oxime 4 mg + praziquantel 10 mg, film-coated tablet for cats 0.5-2 kg
Assessed clinical scopeCat · Full labelled species-specific scope for mixed susceptible cestode and nematode infections, with applicable eyeworm, lungworm or heartworm roles only when the fixed combination is indicated · By mouth
Care settingWeight-band tablet given with or after food after parasite identification, heartworm-risk assessment and confirmation that both active components are clinically justified
vetman score 8.6/10 Very good
Evidence confidence: High Georgia: No · Verified on 15 Oct 2026

A mature, strongly supported broad anthelmintic combination for correctly selected mixed infections; absence from the reviewed Georgian register does not negate its evidence, but local legal supply and the exact label must be checked.

Regulatory and scientific credibility9.0/10

A mature reference line with current UK authorisations and extensive post-authorisation history; the exact forms are not registered in the reviewed Georgian register.

Clinical efficacy9.0/10

Controlled and field studies support broad cestode and nematode efficacy, including label-specific eyeworm and heartworm roles; the evidence base is mature but target and regimen remain parasite-specific.

Safety and tolerability8.0/10

Safety is generally favourable at labelled doses, but microfilaraemic animals can react, MDR1-sensitive dogs need strict dosing, severe renal or hepatic dysfunction and very young or underweight animals require label-specific restrictions, and neurologic or gastrointestinal adverse effects can occur.

Clinical practicality8.5/10

Weight-band tablets and single-dose intestinal-worm treatment are practical, but administration with food, accurate half-tablet use where authorised and parasite-specific weekly or monthly repeat schedules must be followed; unnecessary repeated praziquantel should be avoided.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Use the fixed combination only when cestodes and nematodes, heartworm prevention or another exact combined label role are indicated at the same time; avoid unnecessary exposure to either component.
  • Before heartworm prevention or treatment in an endemic area, establish infection and microfilariae status; a high circulating microfilarial burden can cause acute hypersensitivity-type reactions after treatment.
  • Use caution with other macrocyclic lactones or P-glycoprotein substrates/inhibitors and follow the exact label; toxicity risk can rise in susceptible patients.
  • For Dipylidium, control fleas and chewing lice to prevent reinfection; for Echinococcus, apply local zoonosis reporting, hygiene and disposal requirements.
  • Weigh accurately and use only the matching feline tablet and authorised split. Observe minimum age and weight limits; severe renal or hepatic dysfunction requires the exact label benefit-risk restriction.
Assessment sources
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Formulation Type
Scored tablet
Administration route
By mouth
Manufacturer
Elanco · United States
Registration
Georgia No
EU Yes, veterinary
Verified on: 15 Oct 2026
UK Yes, veterinary
Verified on: 15 Oct 2026
US No
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
DoseSpeciesWeightRouteFrequencySource
1/2 tablet
Minimum recommended dose rate: 2 mg of milbemycin oxime and 5 mg of praziquantel per kg are given as a single dose. 0.5 – 1 kg ½ tablet > 1 - 2 kg 1 tablet Do not use in cats of less than 6 weeks of age and/or weighing less than 0.5 kg. Can be used during pregnancy and lactation.
Cat 0.5–1 kg By mouth once Product label (SPC)
1 tablet
> 1 - 2 kg 1 tablet
Cat 1–2 kg By mouth once Product label (SPC)
No dose for this species
This tablet is for cats; no canine dose is provided on the label. For dogs, use Milbemax 2.5/25 mg or 12.5/125 mg.
Dog Any weight By mouth - Product label (SPC)
12.5 mg/125 mg, Tablet · Cat Any weight Cat Any weight No dose for this species
This tablet is for dogs; no feline dose is provided on the label. For cats, use Milbemax 4/10 mg or 16/40 mg.
- Georgia No
12.5 mg/125 mg, Tablet · Dog 5–25 kg Dog 5–25 kg 1 tablet
Minimum recommended dose rate: 0.5 mg of milbemycin oxime and 5 mg of praziquantel per kg are given once. 5-25 kg 1 tablet >25 - 50 kg 2 tablets >50- 75 kg 3 tablets Do not use in dogs weighing less than 5 kg the recommended dose should be strictly observed Can be used during pregnancy and lactation.
· once
once Georgia No
12.5 mg/125 mg, Tablet · Dog 25–50 kg Dog 25–50 kg 2 tablets
>25 - 50 kg 2 tablets
· once
once Georgia No
12.5 mg/125 mg, Tablet · Dog 50–75 kg Dog 50–75 kg 3 tablets
>50- 75 kg 3 tablets
· once
once Georgia No
Details: pack, label wording, sources, registration

Milbemax 12.5 mg/125 mg, Tablet

milbemycin oxime 12.5 mg + praziquantel 125 mg, tablet for dogs from 5 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
8.6/10
Very good
vetman assessment

Milbemax

12.5 mg/125 mg, milbemycin oxime 12.5 mg + praziquantel 125 mg, tablet for dogs from 5 kg
Assessed clinical scopeDog · Full labelled species-specific scope for mixed susceptible cestode and nematode infections, with applicable eyeworm, lungworm or heartworm roles only when the fixed combination is indicated · By mouth
Care settingWeight-band tablet given with or after food after parasite identification, heartworm-risk assessment and confirmation that both active components are clinically justified
vetman score 8.6/10 Very good
Evidence confidence: High Georgia: No · Verified on 15 Oct 2026

A mature, strongly supported broad anthelmintic combination for correctly selected mixed infections; absence from the reviewed Georgian register does not negate its evidence, but local legal supply and the exact label must be checked.

Regulatory and scientific credibility9.0/10

A mature reference line with current UK authorisations and extensive post-authorisation history; the exact forms are not registered in the reviewed Georgian register.

Clinical efficacy9.0/10

Controlled and field studies support broad cestode and nematode efficacy, including label-specific eyeworm and heartworm roles; the evidence base is mature but target and regimen remain parasite-specific.

Safety and tolerability8.0/10

Safety is generally favourable at labelled doses, but microfilaraemic animals can react, MDR1-sensitive dogs need strict dosing, severe renal or hepatic dysfunction and very young or underweight animals require label-specific restrictions, and neurologic or gastrointestinal adverse effects can occur.

Clinical practicality8.5/10

Weight-band tablets and single-dose intestinal-worm treatment are practical, but administration with food, accurate half-tablet use where authorised and parasite-specific weekly or monthly repeat schedules must be followed; unnecessary repeated praziquantel should be avoided.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Use the fixed combination only when cestodes and nematodes, heartworm prevention or another exact combined label role are indicated at the same time; avoid unnecessary exposure to either component.
  • Before heartworm prevention or treatment in an endemic area, establish infection and microfilariae status; a high circulating microfilarial burden can cause acute hypersensitivity-type reactions after treatment.
  • Use caution with other macrocyclic lactones or P-glycoprotein substrates/inhibitors and follow the exact label; toxicity risk can rise in susceptible patients.
  • For Dipylidium, control fleas and chewing lice to prevent reinfection; for Echinococcus, apply local zoonosis reporting, hygiene and disposal requirements.
  • Weigh accurately and observe minimum age and weight limits. In Collies, related breeds or suspected MDR1 deficiency, never exceed the label dose; severe renal or hepatic dysfunction requires the exact label benefit-risk restriction.
Assessment sources
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Formulation Type
Tablet
Administration route
By mouth
Manufacturer
Elanco · United States
Registration
Georgia No
EU Yes, veterinary
Verified on: 15 Oct 2026
UK Yes, veterinary
Verified on: 15 Oct 2026
US No
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
DoseSpeciesWeightRouteFrequencySource
No dose for this species
This tablet is for dogs; no feline dose is provided on the label. For cats, use Milbemax 4/10 mg or 16/40 mg.
Cat Any weight By mouth - Product label (SPC)
1 tablet
Minimum recommended dose rate: 0.5 mg of milbemycin oxime and 5 mg of praziquantel per kg are given once. 5-25 kg 1 tablet >25 - 50 kg 2 tablets >50- 75 kg 3 tablets Do not use in dogs weighing less than 5 kg the recommended dose should be strictly observed Can be used during pregnancy and lactation.
Dog 5–25 kg By mouth once Product label (SPC)
2 tablets
>25 - 50 kg 2 tablets
Dog 25–50 kg By mouth once Product label (SPC)
3 tablets
>50- 75 kg 3 tablets
Dog 50–75 kg By mouth once Product label (SPC)
16 mg/40 mg, Scored tablet · Cat 2–4 kg Cat 2–4 kg 1/2 tablet
Minimum recommended dose rate: 2 mg of milbemycin oxime and 5 mg of praziquantel per kg are given as a single dose. 2 - 4 kg ½ tablet > 4 - 8 kg 1 tablet > 8 - 12 kg 1½ tablets Do not use in cats weighing less than 2 kg. Can be used during pregnancy and lactation.
· once
once Georgia No
16 mg/40 mg, Scored tablet · Cat 4–8 kg Cat 4–8 kg 1 tablet
> 4 - 8 kg 1 tablet
· once
once Georgia No
16 mg/40 mg, Scored tablet · Cat 8–12 kg Cat 8–12 kg 1 1/2 tablets
> 8 - 12 kg 1½ tablets
· once
once Georgia No
16 mg/40 mg, Scored tablet · Dog Any weight Dog Any weight No dose for this species
This tablet is for cats; no canine dose is provided on the label. For dogs, use Milbemax 2.5/25 mg or 12.5/125 mg.
- Georgia No
Details: pack, label wording, sources, registration

Milbemax 16 mg/40 mg, Scored tablet

milbemycin oxime 16 mg + praziquantel 40 mg, film-coated tablet for cats from 2 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Cat
8.6/10
Very good
vetman assessment

Milbemax

16 mg/40 mg, milbemycin oxime 16 mg + praziquantel 40 mg, film-coated tablet for cats from 2 kg
Assessed clinical scopeCat · Full labelled species-specific scope for mixed susceptible cestode and nematode infections, with applicable eyeworm, lungworm or heartworm roles only when the fixed combination is indicated · By mouth
Care settingWeight-band tablet given with or after food after parasite identification, heartworm-risk assessment and confirmation that both active components are clinically justified
vetman score 8.6/10 Very good
Evidence confidence: High Georgia: No · Verified on 15 Oct 2026

A mature, strongly supported broad anthelmintic combination for correctly selected mixed infections; absence from the reviewed Georgian register does not negate its evidence, but local legal supply and the exact label must be checked.

Regulatory and scientific credibility9.0/10

A mature reference line with current UK authorisations and extensive post-authorisation history; the exact forms are not registered in the reviewed Georgian register.

Clinical efficacy9.0/10

Controlled and field studies support broad cestode and nematode efficacy, including label-specific eyeworm and heartworm roles; the evidence base is mature but target and regimen remain parasite-specific.

Safety and tolerability8.0/10

Safety is generally favourable at labelled doses, but microfilaraemic animals can react, MDR1-sensitive dogs need strict dosing, severe renal or hepatic dysfunction and very young or underweight animals require label-specific restrictions, and neurologic or gastrointestinal adverse effects can occur.

Clinical practicality8.5/10

Weight-band tablets and single-dose intestinal-worm treatment are practical, but administration with food, accurate half-tablet use where authorised and parasite-specific weekly or monthly repeat schedules must be followed; unnecessary repeated praziquantel should be avoided.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Use the fixed combination only when cestodes and nematodes, heartworm prevention or another exact combined label role are indicated at the same time; avoid unnecessary exposure to either component.
  • Before heartworm prevention or treatment in an endemic area, establish infection and microfilariae status; a high circulating microfilarial burden can cause acute hypersensitivity-type reactions after treatment.
  • Use caution with other macrocyclic lactones or P-glycoprotein substrates/inhibitors and follow the exact label; toxicity risk can rise in susceptible patients.
  • For Dipylidium, control fleas and chewing lice to prevent reinfection; for Echinococcus, apply local zoonosis reporting, hygiene and disposal requirements.
  • Weigh accurately and use only the matching feline tablet and authorised split. Observe minimum age and weight limits; severe renal or hepatic dysfunction requires the exact label benefit-risk restriction.
Assessment sources
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Formulation Type
Scored tablet
Administration route
By mouth
Manufacturer
Elanco · United States
Registration
Georgia No
EU Yes, veterinary
Verified on: 15 Oct 2026
UK Yes, veterinary
Verified on: 15 Oct 2026
US No
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
DoseSpeciesWeightRouteFrequencySource
1/2 tablet
Minimum recommended dose rate: 2 mg of milbemycin oxime and 5 mg of praziquantel per kg are given as a single dose. 2 - 4 kg ½ tablet > 4 - 8 kg 1 tablet > 8 - 12 kg 1½ tablets Do not use in cats weighing less than 2 kg. Can be used during pregnancy and lactation.
Cat 2–4 kg By mouth once Product label (SPC)
1 tablet
> 4 - 8 kg 1 tablet
Cat 4–8 kg By mouth once Product label (SPC)
1 1/2 tablets
> 8 - 12 kg 1½ tablets
Cat 8–12 kg By mouth once Product label (SPC)
No dose for this species
This tablet is for cats; no canine dose is provided on the label. For dogs, use Milbemax 2.5/25 mg or 12.5/125 mg.
Dog Any weight By mouth - Product label (SPC)
Active substance doses, with sources
Active substance Milbemycin oxime
Dose calculatorCalculates the active-substance amount; it is not a prescription.
PatientSpecies and weight will be filled in automatically in other calculators.
Selected dose
Dose Species Indication Route Frequency Source
0.5 mg/kg Dog Maintenance By mouth once
VMD SPC 2025
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Milpro 2.5 mg/25 mg film-coated tablets for small dogs and puppies - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2025
2 mg/kg Cat Maintenance By mouth once
VMD SPC 2025
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Milpro 4 mg/10 mg film-coated tablets for small cats and kittens - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2025
Active substance Praziquantel
Dose calculatorCalculates the active-substance amount; it is not a prescription.
PatientSpecies and weight will be filled in automatically in other calculators.
Selected dose
Dose Species Indication Route Frequency Source
5 mg/kg Dog, Cat Maintenance By mouth once
VMD SPC 2022
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Krka Multiwormer 50/144/150 mg tablets for dogs - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2022
VMD SPC 2024
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Krka Wormer 230 mg/20 mg film-coated tablets for cats - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2024

Known Contraindications

  • Critical Milbemycin oxime
    Do not use in cases of hypersensitivity to the active substances or to any of the excipients.
    Sources: VMD SPC · VMD
  • Critical Milbemycin oxime
    Severe kidney impairment: one product label lists marked kidney or liver dysfunction as a contraindication. Another notes that no studies exist in severely debilitated dogs or in animals with seriously impaired kidney or liver function, and does not recommend use in them, or only after a benefit-risk assessment.
    Sources: VMD SPC · VMD
  • Critical Milbemycin oxime
    Severe liver impairment: one product label lists marked kidney or liver dysfunction as a contraindication. Another does not recommend use in animals with seriously impaired kidney or liver function, or only after a benefit-risk assessment.
    Sources: VMD SPC · VMD
  • Critical Milbemycin oxime (Dog)
    Do not use in puppies of less than 2 weeks of age and/or weighing less than 0.5 kg.
    Sources: VMD SPC · VMD
  • Critical Milbemycin oxime (Cat)
    Do not use in kittens of less than 6 weeks of age and/or weighing less than 0.5 kg.
    Sources: VMD SPC · VMD
  • Warning Milbemycin oxime
    Emaciated, severely debilitated animals and animals with an infectious disease: one product label excludes them from deworming; another does not recommend use in severely debilitated animals, or only after a benefit-risk assessment.
    Sources: VMD SPC · VMD
  • Warning Milbemycin oxime (Dog)
    the margin of safety in certain dogs of Collie or related breeds is less than in other breeds. In these dogs, the recommended dose should be strictly observed. The tolerance of the veterinary medicinal product in young puppies from these breeds has not been investigated.
    Sources: VMD SPC · VMD
  • Warning Milbemycin oxime (Dog)
    The use in dogs suffering from microfilaremia is thus not recommended. In the case of a positive diagnosis, adulticidal therapy is indicated before administering the veterinary medicinal product.
    Sources: VMD SPC · VMD
  • Caution Milbemycin oxime
    In a study, this combination of active substances was demonstrated to be well tolerated in breeding bitches, including during pregnancy and lactation. As a specific study with this veterinary medicinal product has not been performed, use during pregnancy and lactation only according to the benefit-risk assessment
    Sources: VMD SPC · VMD
  • Caution Milbemycin oxime
    use during pregnancy and lactation only according to the benefit-risk assessment by the responsible veterinarian.
    Sources: VMD SPC · VMD
  • Caution Milbemycin oxime (Cat)
    In the absence of data on cats with microfilaraemia, its use should be according to a benefit risk assessment by the attending veterinarian.
    Sources: VMD SPC · VMD
  • Critical Praziquantel
    Do not use in cases of known hypersensitivity to the active substances or to any of the excipients.
    Sources: VMD SPC · VMD
  • Known Breed Sensitivities Milbemycin oxime
    Collie, Collie (unspecified), Collie - Scottish Rough, Collie - Scottish Smooth, Sheepdog - Old English, Sheepdog - Shetland (Sheltie), Shetland Sheepdog
    the margin of safety in certain dogs of Collie or related breeds is less than in other breeds. In these dogs, the recommended dose should be strictly observed.

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.